Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.
Scientists have used powerful microscopes to look at sticky fragments of the Huntington’s disease protein, shedding light on these structures which are thought to drive the disease
Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.
HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.
uniQure is conducting safety trials of the first gene therapy for HD. A recent press release provided a 1 year update on the first group of 10 people who underwent surgery to receive this experimental drug. Let’s talk more about what it means.
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022
Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntington’s disease observational trials to model progression of the disease. They hope their findings will help improve clinical trial design.